Fiche publication
Date publication
avril 2019
Journal
Revue des maladies respiratoires
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DALSTEIN Véronique
,
Pr POLETTE Myriam
,
Dr NAWROCKI-RABY Béatrice
Tous les auteurs :
Da Silva J, Dalstein V, Polette M, Nawrocki-Raby B
Lien Pubmed
Résumé
Lung cancer is the most diagnosed and deathly type of cancer worldwide. It has a poor prognosis because of a late diagnosis, high metastatic potential and resistance to conventional therapies. Since the 2000s, the emergence of targeted therapies has improved patients' outcomes. However, these therapies concern only a small proportion of patients, selected by the presence of molecular biomarkers that indicate the targeting relevance. Here, we discuss the possibility that new phenotypical biomarkers could be predictive factors for targeted therapies in lung cancer.
Mots clés
Biomarqueurs phénotypiques, CBNPC, EMT, NSCLC, Phenotypical biomarkers, TEM, Targeted therapies, Thérapies ciblées
Référence
Rev Mal Respir. 2019 Apr 19;:
